Drug intelligence / Profile preview

Nigrinil

Development stage: Unknown
Lead developer: JACKS
Modality: Small Molecules
Administration: Topical

Overview

**Nigrinil** is a JAKS Pharma topical pigmentation-repair cream marketed for hyperpigmentation and dark, thickened skin patches associated with acanthosis nigricans. Product listings identify retinol, lactic acid, glycolic acid, and urea as active ingredients; the formulation is intended to support epidermal turnover, keratolysis, hydration, and improvement in the visible appearance of uneven pigmentation and rough skin. JAKS Pharma lists Nigrinil Cream in its hyperpigmentation portfolio with an approved status. ([amazon.in](https://www.amazon.in/JAKS-PHARMA-Nigrinil-Pigmentation-Underarms/dp/B0DWT2QYGN))

Brand names: Nigrinil
Other names: Nigrinil CreamNigrinil Pigmentation Repair Cream

Targets

RARA (Retinoic acid receptor alpha)

Beyond the preview

Go deeper on Nigrinil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nigrinil.

Explore the full profile